SecBot SecBot

VRTX drug pipeline

$531.45
−1.2% 1-day · Nov 17
Next catalyst
Nov 30, 2026
povetacicept PDUFA date · in 13 days
Typical move on FDA news
±2.2%
1-day, median of 9 events
IV rank
Subscribers
Current print for subscribers
Rated drugs
11
2 bullish · 9 neutral
Phase 3 trials
5
2 with results posted

Upcoming catalysts

3 dated
  1. Nov 30, 202613d
    povetacicept
    PDUFA date · IgA nephropathy (IgAN)
  2. Jan 25, 2027
    JOURNAVX
    Phase 3 primary completion
  3. Feb 2, 2027
    VX-670
    Phase 2 primary completion

Drugs

soonest catalyst first
▲ bullish
Impact
PhaseFiled/PDUFA (BLA under FDA review for accelerated approval in IgAN); Phase 3 (RAINIER in IgAN); Phase 2b/3 (OLYMPUS in p
Time to marketPDUFA target action date of November 30, 2026 for accelerated approval in IgAN; if approved, launch could follow within weeks to months. Confirmatory Phase 3 data and potential pMN approval would follow in subsequent years.

povetacicept Updated Aug 27

13days
Next catalyst
PDUFA date · Nov 30, 2026 · IgA nephropathy (IgAN)
What to watch

The key binary event is the PDUFA date of November 30, 2026 for accelerated approval in IgA nephropathy. For Vertex, a diversified large-cap biotech, this is a pipeline-expansion catalyst rather than a make-or-break event, approval would open a new kidney-disease franchise, while a delay or CRL would be a setback but not existential. Watch for any FDA AdCom announcement and the BLA rolling submission completion before year-end.

Bull case
  • Povetacicept is the only dual BAFF+APRIL inhibitor in pivotal trials for multiple kidney diseases, a differentiated mechanism that targets both B-cell and autoantibody pathways driving IgAN and pMN.
  • The RAINIER Phase 3 trial in IgAN met its primary and all secondary endpoints at the Week 36 interim analysis, with strong efficacy and a favorable safety profile (3.8% discontinuation rate vs 8.8% placebo).
  • FDA has accepted the BLA for accelerated approval in IgAN with a PDUFA target action date of November 30, 2026, a clear near-term catalyst.
Bear case
  • Vertex is a large, diversified biotech (~$140B market cap) where the CF franchise dominates revenue, povetacicept is a pipeline asset, not the company's core value driver, so even a strong approval may have a muted impact on VRTX shares.
  • Competition in IgA nephropathy is growing: Tarpeyo (budesonide, Calliditas/Takeda) and Filspari (sparsentan, Travere Therapeutics) are already approved, and other BAFF/APRIL inhibitors are in development, potentially pressuring pricing and market share.
  • The BLA is for accelerated approval based on proteinuria endpoints, a confirmatory trial will still be required post-approval, and failure of the confirmatory trial could lead to withdrawal.
● neutral
Impact
PhasePhase 2/3
Time to marketEnrollment in the pivotal AMPLITUDE trial is complete. The next gateway is the interim analysis expected in early 2027. If positive, Vertex says it could support a US accelerated approval filing. A first approval is unlikely before 2028 given the filing and FDA review timeline.

inaxaplin Updated Nov 2

What to watch

Watch for the AMPLITUDE Phase 2/3 interim analysis readout expected in early 2027. Positive data showing statistically significant eGFR benefit or proteinuria reduction at 48 weeks could trigger an accelerated approval filing and a meaningful stock move upward. A miss or equivocal result would eliminate the accelerated pathway and likely pressure the stock as the program faces a multi-year delay for a full Phase 3 readout. Vertex also reports Q3 2026 earnings today (November 2, 2026), which may include pipeline updates on inaxaplin's regulatory timeline.

Bull case
  • First-in-class potential: no approved therapy exists for APOL1-mediated kidney disease (AMKD), a condition affecting roughly 100,000+ patients in the US alone. Inaxaplin is the most advanced APOL1 inhibitor in clinical development.
  • Phase 2b data showed a clear 42.7% reduction in proteinuria (UACR) at Week 13 in the modest-proteinuria cohort, expanding the addressable patient population beyond the severe-proteinuria group in AMPLITUDE.
  • Phase 2b also showed a signal (17.3% UACR reduction) in AMKD patients with type 2 diabetes, another large subpopulation, further broadening the commercial opportunity.
Bear case
  • The Phase 2b T2DM cohort result (17.3% UACR reduction) had a 95% confidence interval crossing zero, raising uncertainty about efficacy in diabetic AMKD patients.
  • The AMPLITUDE trial is the controlled, blinded pivotal study that really matters. The Phase 2b AMPLIFIED study was open-label (no placebo), so efficacy signals are not definitive.
  • Vertex is a ~$140B market-cap company with many pipeline priorities. Inaxaplin's interim readout in early 2027 may be overshadowed by nearer-term catalysts such as the povetacicept PDUFA on November 30, 2026.
▲ bullish
Impact
PhaseApproved
Time to marketAlready approved and commercially available in the US (since December 2024) and EU (since July 2025).

ALYFTREK vanzacaftor/tezacaftor/deutivacaftor Updated Nov 2

What to watch

ALYFTREK is already approved and commercially ramping; there is no near-term binary catalyst specific to this drug. Investors should watch the ongoing patient switch from Trikafta to Alyftrek as it impacts Vertex's CF revenue growth and royalty rates, and track Vertex's global expansion into new markets. The next major binary event for Vertex as a whole is the November 30, 2026 PDUFA for povetacicept (IgA nephropathy), a different drug.

Bull case
  • ALYFTREK is the first-ever once-daily CFTR modulator, offering a convenience advantage over Trikafta (twice-daily dosing), which is driving rapid patient switching and revenue growth.
  • Sales surged from $53.9M in Q1 2025 to $705.8M in Q3 2026, reaching blockbuster status and representing 21.6% of Vertex's CF sales; Vertex raised full-year 2026 revenue guidance to $13.1-$13.2 billion.
  • The April 2026 label expansion made ~95% of all US CF patients eligible for Vertex CFTR modulators, expanding the addressable population by ~800 additional patients.
Bear case
  • ALYFTREK is cannibalizing Vertex's older blockbuster Trikafta, which still generates ~75% of CF franchise sales; the switch lowers Vertex's blended royalty rate since Alyftrek carries a lower royalty burden, which could pressure margins over time.
  • Vertex remains heavily dependent on cystic fibrosis for roughly 96% of product sales; any future competitor or CF gene therapy breakthrough could threaten the franchise.
  • Heavy spending on new drug launches (Journavx, Casgevy) and the Crinetics deal are keeping profit growth below revenue growth, per Motley Fool reporting on Nov 2, 2026.
● neutral
Impact
PhaseApproved
Time to marketAlready launched and commercially available. The acute pain indication was approved January 30, 2025. Potential label expansion into diabetic peripheral neuropathy would be earliest around 2028 if Phase 3 trials succeed.

JOURNAVX suzetrigine Updated Nov 2

What to watch

JOURNAVX is an approved, commercially de-risked drug with strong early uptake, meaning the acute pain thesis is already playing out. For Vertex stock, the nearer-term binary catalyst is the company's povetacicept PDUFA for IgA nephropathy on November 30, 2026 -- 28 days away. For JOURNAVX specifically, watch for the pace of prescription growth and the eventual Phase 3 DPN readout (likely early 2027), which would determine whether the drug can expand beyond acute pain into the larger chronic pain market.

Bull case
  • First new class of pain medicine approved in over 20 years: offers a non-opioid, non-addictive option for acute pain where opioid alternatives have been lacking for decades.
  • Rapid commercial growth: Q3 2026 revenue of $58 million, up 71% sequentially from Q1 to Q2 and 18% from Q2 to Q3, with roughly 750,000 prescriptions filled in Q3 2026.
  • Large untapped market: over 80 million Americans are prescribed medication for acute pain each year, and opioid alternatives have been a major unmet need.
Bear case
  • Still a very small fraction of Vertex's business: JOURNAVX's Q3 2026 revenue ($58M) is dwarfed by Vertex's total Q3 revenue of $3.44 billion, which is dominated by the cystic fibrosis franchise.
  • FDA narrowed label expansion ambitions: in August 2025, Vertex acknowledged the FDA was not amenable to a broad peripheral neuropathy label, forcing a more focused development plan.
  • Phase 3 DPN results are unproven: diabetic neuropathic pain involves different pain pathways than acute pain, making positive readouts uncertain.
● neutral
Impact
PhaseApproved
Time to marketAlready approved and marketed since October 2019 (US).

TRIKAFTA elexacaftor/tezacaftor/ivacaftor Updated Nov 2

What to watch

Trikafta itself has no pending regulatory catalyst. Watch Vertex's Q3 2026 earnings (today, Nov 2) for any CF revenue trends and management commentary on the Alyftrek transition, plus the November 30 PDUFA for povetacicept in IgA nephropathy. The CF Buyers' Club/Beximco generic effort ("Triko") is a developing patient-access story but faces US importation-law barriers and no near-term patent disruption given protection into 2037-2038.

Bull case
  • Trikafta remains the dominant CF treatment worldwide with $10.3B in revenue (85% of Vertex's total in FY2025). The April 2026 FDA label extension expanded eligibility to ~95% of all US CF patients (adding ~800 rare CFTR variants), opening a new addressable population.
  • Patent protection extends to at least 2037-2038 (DrugPatentWatch, GreyB), giving Vertex a long exclusivity runway with no threat from US generic competition.
  • Analyst consensus is strong: 32 Buy/Strong Buy ratings vs 1 Strong Sell, with a mean price target of ~$571 and several firms raising targets in recent months (RBC Capital, UBS, Barclays).
Bear case
  • Sales growth is decelerating: Trikafta/Kaftrio revenue was $10.31B in FY2025, up only 0.7% YoY, and Q2 2026 Trikafta revenue of $2.5B was down 1.5% from $2.54B a year earlier (YCharts data). The label expansion in April 2026 may cushion but the near-term growth is flattening.
  • Vertex's own next-gen CF drug Alyftrek (vanzacaftor triple) is cannibalizing Trikafta. In Q2 2026, Alyftrek generated $574M vs zero a year ago, directly eating into Trikafta's patient base.
  • The FDA added a boxed warning for drug-induced liver injury and liver failure in June 2026, which could dampen prescriber confidence and patient compliance.
● neutral
Impact
PhasePhase 2a
Time to marketAt least 3-5 years away, assuming positive Phase 2a results (primary completion July 2027) followed by successful pivotal trials and regulatory review.

VX-407 Updated Nov 2

What to watch

The next hard catalyst for VX-407 is the AGLOW Phase 2a primary completion, estimated for July 2027. Positive proof-of-concept data on height-adjusted total kidney volume (htTKV) would establish VX-407 as a viable precision-medicine approach in ADPKD, while negative or null results would likely end the program. Investors should watch for interim data updates and enrollment/regulatory milestones in the coming quarters, but the far more impactful near-term catalyst for VRTX stock is the November 30, 2026 PDUFA date for povetacicept in IgA nephropathy.

Bull case
  • VX-407 is a first-in-class small molecule corrector designed to address the underlying cause of ADPKD by correcting defective PC1 folding, a novel mechanism compared to the only approved therapy (tolvaptan).
  • Vertex has a strong track record of successfully developing small molecule correctors, as demonstrated in cystic fibrosis, bolstering confidence in the platform approach.
  • If successful, VX-407 would be the first targeted therapy for PKD1-variant ADPKD, addressing a high unmet need in a life-shortening genetic kidney disease with only one approved drug.
Bear case
  • VX-407 targets only ~10% of the ADPKD population (~25,000 patients), limiting its peak revenue potential even if approved.
  • The AGLOW Phase 2a study is single-arm and open-label with only 26 patients, providing a limited dataset for proof-of-concept; a failed readout would halt the program.
  • Vertex already has a deep pipeline (CF franchise, povetacicept, inaxaplin, diabetes, pain), so VX-407 is a small component of the overall valuation; even a positive readout may not move the stock meaningfully.
● neutral
Impact
PhasePhase 1/2
Time to marketLikely many years away. The Phase 1/2 trial is just beginning recruitment with no human data yet reported. If successful, a registrational Phase 3 program and regulatory reviews would add several more years.

VX-017 Updated Nov 2

What to watch

Watch for the first Phase 1/2 safety and efficacy readout from VX-017 in the master protocol NCT04786262. The sibling asset zimislecel (VX-880) posted impressive insulin-independence data (10 of 12 full-dose recipients at one year), setting a high bar. VX-017's key differentiator will be blood-type-independence, but no human data exists yet. Given Vertex's size and pipeline breadth, even a positive early readout is unlikely to move the stock more than a couple percent.

Bull case
  • Blood-type-independent / universal donor design could dramatically expand the addressable type 1 diabetes patient population if successful, eliminating the need for blood-type matching.
  • Vertex has deep cell-therapy manufacturing expertise and a validated master protocol (NCT04786262) already enrolling patients. The sibling program zimislecel (VX-880) proves the islet-cell-replacement concept works in humans.
  • IND clearance by the FDA signals that preclinical safety and manufacturing data were adequate. Vertex explicitly plans to move VX-017 into Phase 1/2 clinical testing in the near term.
Bear case
  • Extremely early stage: no human clinical data reported yet, IND only cleared in August 2026. Cell therapies for type 1 diabetes face long timelines, manufacturing complexity, and chronic immunosuppression requirements.
  • The blood-type-independent / universal donor feature is unvalidated in humans. Durability, safety, and potency of the cells are unknown.
  • Vertex's more advanced islet cell therapy zimislecel (VX-880) already shows strong efficacy (10/12 insulin-independent at one year), implying VX-017 needs to differentiate on more than blood-type compatibility to justify its development cost.
● neutral
Impact
PhasePhase 1 completed / Phase 2 ongoing
Time to marketIf Phase 2 and Phase 3 trials are successful, a potential approval would likely be 4-6 years away, though Vertex could potentially leverage its established CF regulatory pathway to accelerate development.

VX-828 Updated Nov 2

What to watch

The Phase 2 proof-of-concept readout for VX-828 is expected by late 2026 but has no hard date. Positive data showing lung function improvement in the F/MF genotype would validate Vertex's next-generation CFTR corrector platform but is unlikely to move VRTX materially given the stock is driven by the povetacicept PDUFA (Nov 30, 2026), suzetrigine launch, and the broad CF franchise.

Bull case
  • Phase 1 data (Q3 2026) showed the triple combination containing VX-828 was 'safe and well tolerated' in people with CF with the F/MF genotype, supporting advancement.
  • VX-828 is Vertex's first next-generation '3.0' CFTR corrector, designed to bring more patients to near-normal CFTR function, potentially expanding the treated population.
  • A Phase 2 proof-of-concept study (VX25-828-101) is underway; favorable UK ethics opinion obtained in June 2026 and results expected in H2 2026.
Bear case
  • CF is a competitive space; Vertex already dominates with Trikafta/Alyftrek, so incremental improvement from a 3.0 corrector may face high commercial bars and payer scrutiny.
  • Phase 2 proof-of-concept failure or underwhelming efficacy data in the F/MF genotype would halt VX-828 development, though the impact on VRTX shares would be modest given the diversified pipeline.
  • The Phase 2 study is early-stage and small (~152 patients); even positive readouts must clear larger Phase 3 trials years away.
● neutral
Impact
PhasePhase 2
Time to marketAt least several years away, if successful. The DPN Phase 2 data is expected in mid-2027, and Phase 3 trials would follow. No regulatory filings are imminent.

VX-993 Updated Nov 2

What to watch

The next catalyst is the Phase 2 DPN topline readout expected in mid-2027; a positive result could revive the program's prospects in chronic pain, while a negative readout would likely end it. For Vertex, this is one of many pipeline programs, but investors should watch upcoming quarterly updates for enrollment-completion confirmation.

Bull case
  • VX-993 addresses a large unmet need: chronic pain affects millions, and non-opioid alternatives are a major market opportunity following Journavx's launch.
  • Vertex has deep expertise in NaV1.8 biology (Journavx was approved in Jan 2025), and VX-993 could be a complementary or next-gen asset in the same class.
  • DPN afflicts roughly 20-30% of diabetes patients; even a modest market share in chronic neuropathic pain could generate meaningful revenue for Vertex.
Bear case
  • The Phase 2 acute pain trial failed to beat placebo, raising questions about VX-993's fundamental efficacy as a NaV1.8 inhibitor versus the already-approved Journavx (suzetrigine).
  • Vertex already has suzetrigine (Journavx) in Phase 3 for DPN with results due mid-2027; VX-993 may be redundant in Vertex's pain portfolio.
  • The Phase 2 DPN trial remains in recruiting status as of October 2026, with completion of enrollment pushed to end of 2026 (the initial completion date of May 2026 has passed).
● neutral
Impact
PhasePhase 1
Time to marketNot applicable; VX-272 is in Phase 1 healthy-volunteer studies and has not yet entered patient trials. If successfully developed, approval would be several years away, and Vertex has said it may select only the best of its multiple next-gen corrector candidates to advance.

VX-272 Updated Nov 2

What to watch

VX-272 has no imminent catalyst. The single active Phase 1 trial (NCT07437105) has a primary completion date around March 2027. Vertex is running multiple next-gen correctors (VX-581, VX-272, VX-828) in parallel and has said it expects to advance the best asset into further development. For Vertex shareholders, the more material near-term catalysts are the povetacicept PDUFA (IgA nephropathy) on November 30, 2026, and the inaxaplin pivotal readout in early 2027. VX-272 data, when it comes, will inform whether Vertex has a potential successor to its CF franchise, but Phase 1 healthy-volunteer safety/PK data alone is unlikely to be a stock-moving event for a company of Vertex's size.

Bull case
  • Vertex has a dominant CF franchise and VX-272 is part of a next-gen '3.0' CFTR corrector pipeline designed to potentially improve upon ALYFTREK/TRIKAFTA, extending the company's CF leadership.
  • Vertex is running multiple next-gen correctors (VX-581, VX-272, VX-828) in parallel to select the best candidate, increasing the odds of at least one successful successor asset.
  • The Q3 2026 earnings release confirms VX-272 is still actively enrolling and progressing, with plans to study both VX-581 and VX-272 in CF patients to establish proof of concept.
Bear case
  • VX-272 is extremely early stage (Phase 1 in healthy volunteers) with no clinical efficacy data; most early-stage CFTR correctors fail due to safety or insufficient potency.
  • It is one of several next-gen correctors Vertex is advancing, and the company has said it expects to select only the best asset; VX-272 may be deprioritized in favor of VX-581 or VX-828.
  • The CF market is already well-served by Vertex's existing products; even a successful next-gen corrector faces a high bar to show meaningful differentiation over the current standard of care.
● neutral
Impact
PhasePhase 1
Time to marketNot stated

VX-581 Updated Nov 2

What to watch

The next milestone for VX-581 is the estimated primary completion of its Phase 1 dose-escalation study (NCT07283770) around November 19, 2026. Because this is a small Phase 1 healthy-volunteer safety study, its topline data is unlikely to move VRTX stock meaningfully. The far more consequential near-term catalyst for Vertex is the November 30, 2026 PDUFA for povetacicept in IgA nephropathy, which carries the real binary risk/reward for the stock.

Bull case
  • VX-581 is a next-generation '3.0' CFTR corrector, building on Vertex's dominant CF franchise (Trikafta). If successful, it could extend Vertex's CF leadership into a next-cycle product that maintains the company's monopoly in CFTR modulation for years.
  • Vertex has a proven track record of bringing CFTR modulators through the clinic (Kalydeco, Orkambi, Symdeko, Trikafta). Their deep CF biology expertise improves the probability of technical success for pipeline assets like VX-581.
  • The Phase 1 study tests VX-581 both alone and in combination with Vertex's existing drugs tezacaftor and deutivacaftor, setting up optionality for a future triple-combination regimen that could potentially offer better efficacy or convenience than current options.
Bear case
  • VX-581 is extremely early-stage (Phase 1 healthy volunteers), and most Phase 1 CFTR correctors never reach the market. Vertex has a long history of pipeline attrition in this class beyond its approved drugs.
  • Vertex is simultaneously developing VX-272 and VX-670 alongside VX-581 in the same next-gen corrector class. The company has stated it will advance only the best asset, meaning VX-581 could be dropped entirely if it underperforms its siblings.
  • At a company with ~$140B market cap and multiple blockbuster approved products, even a successful VX-581 would take years to contribute materially to Vertex's revenue, giving it negligible near-term stock impact.

Other drugs in filings and trials

no drug report yet
  • ORKAMBI Last: Approval · Aug 7, 2018
  • SYMDEKO (COPACKAGED) Last: Approval · Feb 12, 2018
  • KALYDECO Last: Approval · Mar 17, 2015
  • CTX001 1 trial
  • Exa-cel 1 trial
  • VX-264 1 trial
  • VX-670 1 trial

Past FDA events & how the stock moved

9 events
DateDrugEvent1 day5 days
Jan 30, 2025JOURNAVXApproval+4.6%+9.0%
Dec 20, 2024ALYFTREKApproval+2.2%+0.7%
Apr 26, 2023TRIKAFTAApproval+2.2%+4.3%
Oct 21, 2019TRIKAFTAApproval+8.4%+10.1%
Aug 7, 2018ORKAMBIApproval+0.2%+0.6%
Feb 12, 2018SYMDEKO (COPACKAGED)Approval+0.8%+5.2%
Jul 2, 2015ORKAMBIApproval+2.1%−2.6%
Mar 17, 2015KALYDECOApproval+1.6%−2.6%
Jan 31, 2012KALYDECOApproval+8.9%+8.2%

Clinical trials

12 Phase 2/3
DrugTrialPhaseStatusEnrolledPrimary completion
VX-670A Phase 1/2 Study of VX-670 in Adult Participants With Myotonic Dystrophy 1 (DM1)Phase 2Active not recruiting47Feb 2, 2027
JOURNAVXEvaluation of the Long-term Safety and Effectiveness of Suzetrigine (SUZ) in Participants With Painful Diabetic Peripheral Neuropathy (DPN)Phase 3Active not recruiting455Jan 25, 2027
povetaciceptAn Open-label Study of Povetacicept in Participants With Autoimmune Cytopenias (RUBY-4)Phase 2Completed30Aug 12, 2026
inaxaplinInaxaplin in Participants With Proteinuric APOL1 Mediated Kidney Disease With or Without ComorbiditiesPhase 2Completed42Jul 20, 2026
CTX001Evaluation of Safety and Efficacy of CTX001 in Pediatric Participants With Transfusion-Dependent β-Thalassemia (TDT)Phase 3Active not recruiting16May 31, 2026
VX-264A Safety, Tolerability, and Efficacy Study of VX-264 in Participants With Type 1 DiabetesPhase 2Active not recruiting7May 29, 2026
VX-522 mRNA therapyA Phase 1/2 Study of VX-522 in Participants With Cystic Fibrosis (CF)Phase 2Completed26Apr 21, 2026
TRIKAFTAEvaluation of Long-term Safety and Efficacy of ELX/TEZ/IVA in Cystic Fibrosis (CF) Participants 2 Years and OlderPhase 3Completed71Jan 29, 2026
TRIKAFTAEvaluation of Elexacaftor/Tezacaftor/Ivacaftor (ELX/TEZ/IVA) in Cystic Fibrosis (CF) Participants 12 to Less Than 24 Months of AgePhase 3Completed · results67Sep 4, 2025
Exa-celA Safety and Efficacy Study Evaluating CTX001 in Subjects With Severe Sickle Cell DiseasePhase 3Completed · results63Jul 7, 2025
VX-993A Study Evaluating Efficacy and Safety of VX-993 for Acute Pain After a BunionectomyPhase 2Completed367May 27, 2025
TRIKAFTATrikafta in Cystic Fibrosis PatientsPhase 2Completed · results42Feb 13, 2024